In the BioHarmony Drug Report Database
Galafold (migalastat) is a small molecule pharmaceutical. Migalastat was first approved as Galafold on 2016-05-25. It is used to treat fabry disease in the USA. It has been approved in Europe to treat fabry disease. It is known to target lysosomal alpha-glucosidase. Galafold’s patents are valid until 2038-05-30 (FDA).
Image (chem structure or protein)